MedTrace Logo

Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris

NCT03900676 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2019-10-01

No results posted yet for this study

Summary

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Dose-ranging Study in the Treatment of Acne Vulgaris,

Conditions

  • Acne Vulgaris

Interventions

DRUG

VB-1953 - 2%

Topical Gel

DRUG

VB-1953 - 0% (Vehicle)

Topical Gel

Sponsors & Collaborators

  • Vyome Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Dr. Shilpi Jain · Vyome Therapeutics Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-09
Primary Completion
2019-11-30
Completion
2020-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03900676 on ClinicalTrials.gov